Abstract 347P
Background
Controversy exists regarding the optimal margin of surgical excision for cutaneous squamous cell carcinoma (cSCC). Japanese clinical practice guidelines for skin cancer (second edition) recommend an excision with a 4–6-mm clinical margin for low-risk cSCC and >6-mm clinical margin for high-risk cSCC. However, it is difficult to follow this guideline for all cSCCs because high-risk cSCCs frequently occur on the face or in older patients. The purpose of this study was to investigate the correlation between surgical margin and prognosis in patients with cSCC.
Methods
Patients with cSCC who underwent surgical excision of the primary site between 2011 and 2019 at Saitama Medical University International Medical Center were included in this retrospective observational study. Patients were divided into two groups: group A (standard surgery with guideline-recommended margin) and group B (modified surgery with narrow margin). Overall survival (OS), relapse-free survival (RFS), local recurrence-free survival (LRFS), regional metastasis-free survival (RMFS), and distant metastasis-free survival (DMFS) were compared between the two groups.
Results
A total of 107 patients with cSCC were included in this study: 39 in group A and 68 in group B. There were no significant differences in patient characteristics such as sex, tumor border, and risk factors; age and tumor size differed between groups. There were no statistically significant differences in OS (p=.470), LRFS (p=.631), RMFS (p=.502), and DMFS (p=.475) between the two groups. However, RFS was significantly lower in group A than in group B (p=.049).
Conclusions
This study did not reveal a significant impact of clinical margin on OS in patients with cSCC. Although this conclusion may have been limited by selection bias, excision with narrower margins than those suggested by current guidelines may be appropriate.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
508P - Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study
Presenter: Jinliang Wang
Session: Poster display session
Resources:
Abstract
525P - Retrospective analysis of outcomes of cisplatin and irinotecan combination chemotherapy for unresectable thymic carcinoma
Presenter: Akito Fukuda
Session: Poster display session
Resources:
Abstract
524P - A study in recurrent small cell lung cancer patients, comparing weekly paclitaxel, irinotecan and temozolomide in second-line: A prospective study from a south Indian tertiary cancer hospital
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
505P - PD-L1 expression in ALK rearranged NSCLC: All questions answered?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
487P - Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
492P - Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer
Presenter: Heekyung Ahn
Session: Poster display session
Resources:
Abstract
513P - Phase II study of vitamin B12 and folate supplementation for patients undergoing chemotherapy with pemetrexed
Presenter: Shingo Kitagawa
Session: Poster display session
Resources:
Abstract
493P - Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single centre experience
Presenter: Sarita Shrivastva
Session: Poster display session
Resources:
Abstract
494P - Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
517P - High BRCA1 expression is independently correlated with decreased overall survival in lung adenocarcinoma: Evidence from meta and bioinformatics analyses
Presenter: Fengzhu Guo
Session: Poster display session
Resources:
Abstract